Application of drug-co-loaded polymer vesicles in drugs for treating acute lymphoblastic leukemia

CN118986884APending Publication Date: 2024-11-22SUZHOU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410611747.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing drug carriers are difficult to carry multiple drugs of different properties efficiently and stably at the same time, resulting in uneven drug release, high toxicity, and the synergy of unknown effects in the treatment of acute lymphocytic leukemia.

Method used

Using amphiphilic block polymers as carriers, the tubulin inhibitors and targeting the oncogene Polo-like kinase 1 inhibitors are formed to form negatively charged reversible crosslinked polymer vesicles in the inner membrane through electrostatic interactions to ensure that The drug is stable in the blood and is released quickly in tumor cells.

Benefits of technology

It achieved efficient and stable loading and synergistic release of drugs, significantly prolonged the survival of mice, reduced tumor infiltration, reduced tumor burden, and had good safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986884A_ABST
    Figure CN118986884A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a drug-co-loaded polymer vesicle in preparation of a drug for treating acute lymphocytic leukemia. The drug-co-loaded polymer vesicle is prepared from an amphiphilic block polymer and two or more than two antitumor drugs. The polymer vesicle co-loaded with the medicine is simple and controllable to prepare, adjustable in medicine proportion, small in size, easy to store, high in stability, excellent in biocompatibility, high in synergistic anti-tumor effect and high in in-vivo safety, and the medicine in cells can be rapidly released in proportion. According to the application of the drug-co-loaded polymer vesicles in drugs for treating acute lymphoblastic leukemia, tumor infiltration in mice is greatly reduced, tumor burden of the mice is relieved, the lifetime of the mice is remarkably prolonged, and the drug-co-loaded polymer vesicles have good safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of polymer nanomedicines, and in particular relates to application of drug-co-loaded polymer vesicles in drugs for treating acute lymphocytic leukemia. Background Art

[0002] The oncogene Polo-like kinase 1 (PLK1) is essential for the division and proliferation of tumor cells. It is overexpressed in leukemia and many other types of tumors, and the expression level is closely related to poor prognosis, which has greatly promoted the development of PLK1 molecular targeted drugs. Among them, volacetide (Vol) is the most advanced PLK1 inhibitor in clinical research. It was granted breakthrough therapy status by the FDA in 2013 for the treatment of leukemia patients; however, it has problems such as high in vivo clearance rate, low tumor enrichment, large dosage and severe dose-limiting toxicity, which hinder its clinical application and efficacy. Vincristine sulfate (VCR) is a potent chemotherapy drug that inhibits tubulin polymerization and is widely used in the treatment of acute lymphoblastic leukemia. The liposomal vincristine sulfate (Marqibo ® ) Although nano-drugs and PEG-PLGA polymer nanoparticles loaded with vincristine sulfate can prolong the circulation time of VCR and reduce toxic side effects, it is difficult to achieve Vol encapsulation, and they are large in size, have poor stability, poor controllability of drug release, and have severe neurotoxicity, resulting in a low usable dose.

[0003] When two or more drugs are used, the strength, duration and even nature of one or more drugs may change to varying degrees due to the interaction between the drugs; the absorption, distribution, metabolism and excretion of drugs can often be affected by other drugs used in combination, that is, one drug affects the pharmacokinetics of another drug, causing the efficacy or toxicity to be enhanced or weakened. In the 1960s, researchers found that patients with acute lymphoblastic leukemia (ALL) who received sequential or simultaneous administration of 6-mercaptopurine and methotrexate had similar survival; the researchers concluded that the combination of these two drugs did not change their respective efficacy. Further, the researchers conducted a retrospective analysis of clinical trials involving immune checkpoint inhibitor combination therapy involving 8 different cancer types. The patients' progression-free survival was similar to or shorter than the predicted results based on the effects of independent drugs, indicating that the therapeutic benefits of these combinations are based on independent effects, rather than synergistic or additive effects. Maria Sol Brassesco et al. found that the combination of PLK1 inhibitors and doxorubicin has an antagonistic effect (Cancer Biology & Therapy 2013, 14, 648-657); Marta Halasa et al. found that CDDP and CAM had no synergistic effect on MCF7, 47D, MDA-MB-231, and MDA-MB-468, and IC 50 Higher than a single drug (Int. J. Mol. Sci. 2021, 22, 8573); According to the studies conducted, polymer-loaded CFZ / MID has almost no synergistic effect on the toxicity of Molm-13-Luc, but rather an additive or even antagonistic effect.

[0004] If multiple drugs with different properties can be efficiently and stably encapsulated in the same nanocarrier and used synergistically to treat patients with acute lymphoblastic leukemia (ALL), it will have very good application prospects. Summary of the invention

[0005] The purpose of the invention is to disclose the application of a drug-co-loaded polymer vesicle in the treatment of acute lymphocytic leukemia.

[0006] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical scheme: Provided is a use of a drug-co-loaded polymer vesicle in preparing a drug for treating acute lymphocytic leukemia, wherein the drug comprises two or more anti-tumor drugs.

[0007] Furthermore, the drug-co-loaded polymer vesicles are prepared from an amphiphilic block polymer and two or more anti-tumor drugs, wherein the amphiphilic block polymer is a hydrophilic segment-hydrophobic segment-polypeptide segment.

[0008] Furthermore, the amphiphilic block polymer is a hydrophilic segment-hydrophobic segment-KD z , wherein K is lysine, D is aspartic acid, the hydrophilic segment is a polyethylene glycol segment; the hydrophobic segment is a random copolymer P(A-DTC), A is an ester monomer or a carbonate monomer unit, and DTC is a disulfide five-membered ring carbonate unit; z is 1 to 25; P means polymerization, and P(A-DTC) is a random copolymer of A-DTC.

[0009] Furthermore, the structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-AcKD z , wherein K is lysine, D is aspartic acid, Ac is acetyl, the hydrophilic segment is a polyethylene glycol segment, the hydrophobic segment is a random copolymer P (A-DTC), A is an ester monomer or a carbonate monomer unit, and DTC is a disulfide five-membered ring carbonate unit; z is 1 to 25; the ester monomer is one or two of caprolactone and lactide; and the carbonate monomer is trimethylene carbonate.

[0010] Further, the structure of P(A-DTC) is one of the following structures: .

[0011] Furthermore, the ester monomer is one or both of caprolactone and lactide; and the carbonate monomer is trimethylene carbonate.

[0012] Further, the anti-tumor drug is a combination of a microtubule inhibitor and an inhibitor targeting the oncogene Polo-like kinase 1, wherein the microtubule inhibitor is any one or more of vincristine sulfate, paclitaxel, docetaxel, cabazitaxel, auristatin, maytansine, and eribulin; at least one of the anti-tumor drugs is an inhibitor targeting the oncogene Polo-like kinase 1, wherein the inhibitor targeting the oncogene Polo-like kinase 1 is any one or more of volacetine, reglucicetine, ON01910, BI2536, HMN-214, and GSK461364; preferably, the anti-tumor drug is a combination of vincristine sulfate and volacetine.

[0013] Furthermore, the mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:(1-48); preferably, the mass ratio is 1:(8-32); more preferably, the mass ratio is 1:8, 1:16 or 1:32.

[0014] Furthermore, the actual encapsulation mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1: (1-48). Preferably, the actual encapsulation mass ratio is 1: (12-48); more preferably, the actual encapsulation mass ratio is 1: 12, 1: 24 or 1: 48.

[0015] Furthermore, in the amphiphilic block polymer, the molecular weight of the hydrophilic segment is 2000-10000 Da; the molecular weight of the hydrophobic segment is 2-10 times the molecular weight of the hydrophilic segment; the molecular weight of PDTC is 10%-40% of the total molecular weight of the hydrophobic segment; z is 5-15; Preferably, the molecular weight of the hydrophilic segment is 2000-8000 Da; the molecular weight of the hydrophobic segment is 2-6 times the molecular weight of the hydrophilic segment; the molecular weight of the PDTC segment is 10%-30% of the molecular weight of the hydrophobic segment; More preferably, the molecular weight of the hydrophilic segment is 5000-7500 Da; the molecular weight of the hydrophobic segment is 2-4 times that of the hydrophilic segment; the molecular weight of PDTC is 10%-20% of the total molecular weight of the hydrophobic segment, and z is 5, 10 or 15.

[0016] Furthermore, the amphiphilic block polymer of the present invention comprises a hydrophilic PEG segment (n segment), a hydrophobic segment (x+y segment), a hydrophilic KD z Segment (z segment), hydrophobic segment, KD z The segments are connected by urethane bonds; the amphiphilic block polymer is represented by PEG-P(TMC-DTC)-KD z PEG-P(CL-DTC)-KD z PEG-P(LA-DTC)-KD z , which can be any of the following structures:

[0017] Furthermore, the drug-co-loaded polymer vesicles are used in the preparation of drugs for treating acute lymphocytic leukemia, wherein the drug-co-loaded polymer vesicles are prepared using anti-tumor drugs and amphiphilic block polymers as raw materials.

[0018] A use of a drug-co-loaded polymer vesicle in the preparation of a drug for treating acute lymphoblastic leukemia, wherein the drug-co-loaded polymer vesicle is mainly prepared from an amphiphilic block polymer, a tubulin inhibitor, and a targeted oncogene Polo-like kinase 1 inhibitor, and the structure of the amphiphilic block polymer is any one of the following structures: ; The microtubule inhibitor is vincristine sulfate, and the inhibitor targeting oncogene Polo-like kinase 1 is volacetide.

[0019] Preferably, the mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1:(1-48); further preferably, the mass ratio is 1:(8-32); more preferably, the mass ratio is 1:8, 1:16 or 1:32.

[0020] Furthermore, in the drug-co-loaded polymer vesicles of the present invention, the actual encapsulation mass ratio of the tubulin inhibitor to the oncogene Polo-like kinase 1 inhibitor is 1:(1-48). Preferably, the actual encapsulation mass ratio is 1:(12-48); more preferably, the actual encapsulation mass ratio is 1:12, 1:24 or 1:48.

[0021] Furthermore, the drug-co-loaded polymer vesicles of the present invention are prepared by mixing an anti-tumor drug solution and an amphiphilic block polymer solution, letting the mixture stand, and then dialyzing to obtain drug-co-loaded polymer vesicles; the standing time is 5 to 50 hours, preferably, the standing time is 8 to 30 hours.

[0022] Furthermore, the present invention provides the use of the drug-co-loaded polymer vesicles in the preparation of drugs for inducing apoptosis of acute lymphoblastic leukemia cells.

[0023] Furthermore, the present invention provides the use of the drug-co-loaded polymer vesicles in the preparation of a drug for prolonging the survival of patients with acute lymphoblastic leukemia.

[0024] Furthermore, the present invention provides the use of the drug-co-loaded polymer vesicles in the preparation of a drug for reducing tumor infiltration in patients with acute lymphoblastic leukemia.

[0025] The polymer vesicles in the present invention are reduction-sensitive reversibly cross-linked polymer vesicles with negative charges on the inner membrane, resolvable cross-links in cells and biodegradable; the polymer is PEG-P(A-DTC)-KD z or PEG-P(A-DTC)-AcKD z , where A (TMC or LA or CL) and DTC in the middle block are randomly arranged; KD z / AcKD z The molecular weight of the PEG segment is 700-2000 Da, which is much smaller than that of the PEG segment. After self-assembly and cross-linking, reversibly cross-linked polymer vesicles with negatively charged inner membranes are obtained. The inner shell of the vesicles is KD z / AcKD zUsed for compounding small molecule drugs. The vesicle membrane is a reversibly cross-linked biodegradable and compatible PTMC or PLA or PCL. The dithiolane structure of the side chain is similar to the natural antioxidant lipoic acid in the human body, which can spontaneously form reduction-sensitive reversible cross-links, which can not only ensure the stable and long circulation of drugs in the blood, but also achieve rapid de-cross-linking in cells and quickly release drugs into tumor cells.

[0026] Compared with the prior art, the polymer KD / AcKD of the present invention has good biocompatibility. It can form asymmetric membrane structure vesicles by combining PEG segments and hydrophobic segments, and realize efficient and stable encapsulation of small molecule drugs (such as VCR and Vol). The present invention encapsulates VCR and Vol through electrostatic interaction, and is separated from the outside world by the disulfide cross-linked vesicle membrane, which can avoid leakage during the delivery process and loss and toxic side effects caused by cell adhesion. It can be efficiently delivered to the lesion site, and under the action of the reducing agent glutathione (GSH) in the body, VCR and Vol are quickly released to effectively kill tumor cells. Animal experiments show that Ps-VCR / Vol 1 / 24 The survival time of mice was significantly prolonged, and there was no significant weight loss in mice during the treatment.

[0027] The application of the drug-co-loaded polymer vesicles of the present invention in the treatment of acute lymphoblastic leukemia can efficiently induce cell G2 / M phase arrest, efficiently induce ALL cells to be arrested in the G2 / M phase, thereby promoting cell apoptosis, and can efficiently inhibit the proliferation and peripheral blood infiltration of leukemia cells, has a strong in vivo synergistic anti-B-ALL and T-ALL activity, greatly reduces tumor infiltration in mice, reduces the tumor burden of mice, significantly prolongs the survival of mice, and has good safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 PEG-P(TMC-DTC)-KD in Example 1 10 PEG-P(TMC-DTC)-AcKD 10 NMR spectrum of .

[0029] Figure 2 Schematic diagram of the preparation of Ps-VCR / Vol in Example 2.

[0030] Figure 3 Based on PEG-P(TMC-DTC)-KD in Example 2 10 (A) Particle size distribution of Ps-VCR / Vol and (B) stability upon 100-fold dilution and addition of 10% FBS.

[0031] Figure 4 Based on PEG-P(TMC-DTC)-KD in Example 3 10Toxicity of Ps-VCR in (A) CCRF-CEM and (C) Nalm-6-Luc cells; different ratios of Ps-VCR / Vol and Ps-Vol and free VCR / Vol 1 / 24 Toxicity in (B) CCRF-CEM and (D) Nalm-6-Luc cells (n = 6).

[0032] Figure 5 Based on PEG-P(TMC-DTC)-AcKD in Example 3 10 The anti-ALL activities of Ps-VCR / Vol, Ps-VCR, and Ps-Vol in CCRF-CEM cells (n = 6).

[0033] Figure 6 The (A, C) CCRF-CEM cells and (B, D) Nalm-6-Luc cells in Example 4 were treated with Ps-VCR / Vol 1 / 24 , Ps-VCR, Ps-Vol, free VCR / Vol 1 / 24 or cell cycle arrest after incubation with PBS for 24 h.

[0034] Figure 7 For (A) CCRF-CEM cells and (B) Nalm-6-Luc cells in Example 5 and Ps-VCR / Vol 1 / 24 , Ps-VCR, Ps-Vol and free VCR / Vol 1 / 24 Apoptosis after 48 h of incubation.

[0035] Figure 8 Ps-VCR / Vol in Example 6 1 / 24 With free VCR / Vol 1 / 24 Toxicity to activated human T cells.

[0036] Fig. 9 Schematic diagram of (A) the establishment, drug administration and monitoring of the orthotopic CCRF-CEM T-ALL mouse model in Example 7; (B) Kaplan-Meier survival curve and (C) body weight changes after different treatments.

[0037] Fig.10 (A) Representative scatter plot and (B) quantitative analysis of T-ALL infiltration in peripheral blood of orthotopic CCRF-CEM T-ALL mice after different treatments in Example 7; (C) scatter plot and (D) quantitative analysis of leukemic infiltration in various organs; (E) weight of spleen of mice in different treatment groups (n = 3).

[0038] Fig.11These are the hematoxylin-eosin (H&E) staining images of (A) major organs (liver, spleen, kidney, lung and heart) and (B) femur and tibia of the orthotopic CCRF-CEM mice after different treatments in Example 7.

[0039] Fig.12 (A) micro-CT images of the femur and tibia of mice in different treatment groups and (B) quantitative analysis of various indicators in Example 7 (n = 3). BMD: bone mineral density; BV / TV: bone volume fraction; BS / TV: bone surface area; Tb.Th: trabecular thickness; Tb.N: trabecular number; Tb.Sp: trabecular separation.

[0040] Fig.13 (A) Schematic diagram of the establishment, dosing and monitoring of the patient-derived orthotopic T-ALL PDX mouse model in Example 7; (B) quantitative analysis (n = 3) and (C) representative scatter plots of T-ALL infiltration in the peripheral blood of mice after different treatments; (D) Kaplan-Meier survival curves and (E) body weight changes of mice in different treatment groups (n = 6).

[0041] Fig.14 Schematic diagram of (A) establishment, drug administration and monitoring of the orthotopic Nalm-6-Luc B-ALL mouse model in Example 8; (B) bioluminescence imaging, (C) quantitative analysis, (D) Kaplan-Meier survival curve and (E) body weight changes after different treatments.

[0042] Fig.15 (A) B-ALL infiltration in the liver, spleen, peripheral blood, lung and bone marrow of each group and (B) quantitative analysis after different treatments of the orthotopic Nalm-6-Luc B-ALL mice in Example 8 on day 23; (C) spleen weights of mice in different treatment groups (n = 3).

[0043] Fig.16 These are H&E staining images of the major organs (liver, spleen, kidney, lung and heart) as well as the femur and tibia of the orthotopic Nalm-6-Luc mice in Example 8 after different treatments. DETAILED DESCRIPTION

[0044] Unless otherwise specified, the terms used herein have the following meanings:

[0045] Tubulin inhibitors: Compounds that bind to specific sites on tubulin, affect and interfere with the polymerization and depolymerization dynamics of tubulin, thereby blocking the formation of the M phase spindle and causing tumor cell growth to stagnate at the G2 / M phase, thereby exerting anti-tumor effects. Currently, tubulin inhibitors include vincristine sulfate, paclitaxel, docetaxel, cabazitaxel, auristatin, maytansine, eribulin, etc.

[0046] PLK1 inhibitors: compounds that inhibit the activity of PLK1, causing tumor cell growth inhibition or even apoptosis, but have no significant effect on normal cells. Currently, PLK1 inhibitors include volacetidine, reglucicetidine, ON01910, BI2536, HMN-214, GSK461364, etc.

[0047] Random copolymer: a copolymer in which each monomer unit on the main chain is arranged randomly. If the random copolymer has two monomer units, the monomers M1 and M2 are arranged randomly on the macromolecular chain, and the two monomers are randomly distributed on the main chain. In the present invention, the random copolymer is P(A-DTC), A is an ester monomer or a carbonate monomer unit, and DTC is a disulfide five-membered ring carbonate monomer unit.

[0048] The definition of the drug for treating acute lymphoblastic leukemia described in the present invention includes drugs for inducing apoptosis of acute lymphoblastic leukemia cells, drugs for prolonging the survival of acute lymphoblastic leukemia patients, drugs for reducing tumor infiltration in acute lymphoblastic leukemia patients, etc.

[0049] In the present invention, the chemical structural formula of KDz is as follows:

[0050] The chemical structure of AcKDz is as follows: ; z is 1 to 20, preferably 5 to 15. Preferably, z is 5, 10 or 15.

[0051] The present invention is further described below in conjunction with the examples and drawings. The specific preparation methods and testing methods are conventional techniques in the art. Cell experiments and animal experiments are conventional experiments that meet the relevant requirements of Soochow University. Unless otherwise specified, in the following examples, the amphiphilic block polymer is PEG 5k -P(TMC 15k -DTC 2k )-KD 10 or PEG 5k -P(TMC 15k -DTC 2k )-AcKD 10 ; Vincristine sulfate (VCR), volacetidine (Vol) and other reagents are commercially available raw materials, among which KD10 ,AcKD 10 The synthesis was commissioned by Qiangyao Biotechnology Co., Ltd., and the method used was the conventional peptide preparation method in the prior art. 10 It was prepared by Fmoc solid phase synthesis using Fmoc-Lys(Boc)-OH and Fmoc-Asp(otbu)-OH as raw materials. Its purity was 98.4% as measured by HPLC and its molecular weight was 1297.08 as measured by mass spectrometry. 10 Using Fmoc-Lys(Boc)-OH and Fmoc-Asp(otbu)-OH as raw materials, Fmoc solid phase synthesis was performed until the Fmoc protecting group of the last amino acid was removed, and then DMF solution and 3 equivalents of pyridine / acetic anhydride (1:1) were added at room temperature for 30 min to complete the acetylation. The purity was measured by HPLC to be 98.49%, and the molecular weight was measured by mass spectrometry to be 1339.11.

[0052] Example 1 Polymer PEG-P(TMC-DTC)-KD 10 PEG-P(TMC-DTC)-AcKD 10 Synthesis Polymer PEG-P(TMC-DTC)-KD 10 The terminal hydroxyl group of PEG-P(TMC-DTC) was activated by p-NPC and then reacted with KD 10 The reaction can be obtained by referring to the method disclosed in patent CN201910472613.8 or CN202010845920.9.

[0053] Weigh 85 mg KD 10 The peptide was placed in a double-necked flask and vacuumed for 1 h. Then, 3.5 mL of anhydrous DMSO was added to dissolve it under a nitrogen atmosphere, and 153 mg (210 µL) of triethylamine was added. Then, an anhydrous DMSO solution of PEG-P(TMC-DTC)-NPC (755 mg, 7 mL) was added dropwise and reacted at 30 ºC for 48 h. Subsequently, the reaction solution was placed in a dialysis bag (MWCO: 3500 Da) and dialyzed with DMSO containing 10% anhydrous methanol for 40 h, with the dialysate replaced every 8 h, and then dialyzed with DCM for 8 h, with the dialysate replaced every 4 h. Finally, the white flocculent polymer PEG-P(TMC-DTC)-KD was obtained by precipitation in ice ether and vacuum drying for 48 h. 10 , yield: 87%.

[0054] PEG-P(TMC-DTC)-KD 10 of 1 H NMR spectrum Figure 1As shown, it can be observed that PEG (δ 3.23, δ 3.49), TMC (δ 4.15, δ 1.91), DTC (δ 4.15, δ 3.06) and KD 10 (δ 4.47, δ 1.15), and by comparing the KD at δ4.47 ppm 10 KD was calculated from the peak area of ​​the methine and the TMC methylene at δ 1.91 ppm 10 The grafting rate is 100%.

[0055] Polymer PEG-P(TMC-DTC)-AcKD 10 The terminal hydroxyl group of PEG-P(TMC-DTC) was activated by p-NPC or CDI and then reacted with AcKD 10 Obtained by reaction.

[0056] p-NPC method: Weigh 3 g of PEG-P(TMC-DTC) in a double-necked bottle, evacuate for 1 h, add 30 mL of anhydrous DCM to dissolve under nitrogen atmosphere, add 54.9 μL of pyridine, and transfer to an ice-water bath. Weigh 145 mg of p-NPC and dissolve it in DCM to 110 mg / mL, add it dropwise to the reaction bottle, and after the addition is complete, transfer it to room temperature for 24 hours. After filtration, collect the filtrate and evaporate it, precipitate it in ice ether, and vacuum dry it for 48 h to obtain a white flocculent polymer PEG-P(TMC-DTC)-NPC with a yield of 85%.

[0057] PEG-P(TMC-DTC)-NPC and AcKD 10 Peptide reaction: weigh 100 mg AcKD 10 The peptide was placed in a double-necked flask and vacuumed for 1 h. Then, 4 mL of anhydrous DMSO was added to dissolve it under a nitrogen atmosphere, and 165 mg (227 µL) of triethylamine was added. Then, an anhydrous DMSO solution of PEG-P(TMC-DTC)-NPC (900 mg, 9 mL) was added dropwise and reacted at 30°C for 48 h. Subsequently, the reaction solution was placed in a dialysis bag (MWCO: 3500 Da) and dialyzed with DMSO containing 10% anhydrous methanol for 40 h, with the dialysate replaced every 8 h, and then dialyzed with DCM for 8 h, with the dialysate replaced every 4 h. Finally, the white flocculent polymer PEG-P(TMC-DTC)-AcKD was obtained by precipitation in ice ether and vacuum drying for 48 h. 10 , yield: 88%.

[0058] CDI method: Weigh 2 g of PEG-P(TMC-DTC) in a double-necked bottle, evacuate for 1 h, and then add 10 mL of anhydrous DCM to dissolve it under nitrogen atmosphere. Weigh 55 mg of CDI and dissolve it in 1 mL of DCM, then add it dropwise to the reaction bottle. After the addition is complete, transfer it to 37°C for 4 hours. Finally, precipitate it in ice tert-butyl methyl ether and vacuum dry it for 48 hours to obtain a white flocculent polymer PEG-P(TMC-DTC)-CDI with a yield of 90%.

[0059] PEG-P(TMC-DTC)-CDI and AcKD 10 Peptide reaction: weigh 100 mg AcKD 10 The peptide was placed in a double-necked flask and vacuumed for 1 h. Then, 4 mL of anhydrous DMSO was added to dissolve it under a nitrogen atmosphere, and 165 mg (227 µL) of triethylamine was added. Then, an anhydrous DMSO solution of PEG-P(TMC-DTC)-CDI (900 mg, 9 mL) was added dropwise and reacted at 30°C for 48 h. Subsequently, the reaction solution was placed in a dialysis bag (MWCO: 3500 Da) and dialyzed with DMSO containing 10% anhydrous methanol for 40 h, with the dialysate replaced every 8 h, and then dialyzed with DCM for 8 h, with the dialysate replaced every 4 h. Finally, the white flocculent polymer PEG-P(TMC-DTC)-AcKD was obtained by precipitation in ice ether and vacuum drying for 48 h. 10 , yield: 90%.

[0060] PEG-P(TMC-DTC)-AcKD 10 of 1 H NMR spectrum Figure 1 As shown, it can be observed that PEG (δ 3.23, δ 3.49), TMC (δ 4.13, δ 1.95), DTC (δ 4.13, δ 3.07) and AcKD 10 (δ 8.04, δ 4.48, δ 2.67, δ 1.85, δ 1.23), and by comparing the AcKD at δ 4.48 ppm 10 AcKD was calculated from the peak area of ​​the methine and TMC methylene at δ 1.95 ppm 10 The grafting rate is 100%.

[0061] KD with two primary amino groups 10 In comparison, AcKD 10One of the primary amino groups in the PEG-P(TMC-DTC)-NPC or PEG-P(TMC-DTC)-CDI is modified with an acetyl group. The reaction can be carried out at a fixed point, and the reaction site is fixed to reduce the generation of by-products, making PEG-P(TMC-DTC)-AcKD 10 The structure is clearer, which is conducive to subsequent CMC quality control research.

[0062] Example 2 Preparation of reversibly cross-linked biodegradable vesicles co-loaded with VCR and Vol (Ps-VCR / Vol) Ps-VCR / Vol was prepared by solvent exchange method, in which VCR and Vol were reacted with KD z The electrostatic interaction between them is wrapped in the hydrophilic inner cavity of the vesicle. The preparation diagram is shown in Figure 2 The mass ratios of VCR to Vol were 1∶8, 1∶16 and 1∶32 respectively. Taking 1∶16 as an example, 1.75 mL of Vol DMSO solution (20 mg / mL) was mixed with 4.3 mL PEG-P(TMC-DTC)-KD 10 0.44 mL of VCR aqueous solution (5 mg / mL) was mixed evenly with 38 mL of HEPES solution (5 mM, pH 6.8), and mixed evenly at 37 ºC and 300 rpm. Then, the polymer and Vol DMSO solution were uniformly injected into it, stirred for 15 min, and then transferred to a 37 ºC shaker for static incubation for 12 h. Then, Ps-VCR / Vol was obtained by full dialyzing (MWCO: 3500 Da) with HEPES (5 mM, pH 7.4), and concentrated to a vesicle concentration of about 9 mg / mL by centrifugal ultrafiltration (vivaspin, MWCO: 10 kDa).

[0063] The study found that the particle size of Ps-VCR / Vol obtained at different drug ratios was about 26 nm, and the particle size distribution was about 0.1 (Table 1 and Figure 3 A). The content of VCR was calculated by HPLC (the mobile phase was methanol / water (0.15% triethylamine was added, and the pH was adjusted to 7.0 with phosphoric acid) = 70:30) to measure the absorbance at a wavelength of 298 nm (UV), and the content of Vol was calculated by ultraviolet spectrophotometer (UV-vis) test. The results showed that when the mass feed ratio of VCR to Vol was 1:16, the encapsulation efficiency (DLE) of VCR and Vol was 48.8% and 75.8%, respectively, and the actual encapsulation mass ratio of VCR and Vol was 1:24.8, abbreviated as Ps-VCR / Vol. 1 / 24Similarly, when the mass ratio of VCR to Vol was 1:8 and 1:32, Ps-VCR / Vol 1 / 12 and Ps-VCR / Vol 1 / 48 When Ps-VCR and Ps-Vol were prepared similarly to Ps-VCR / Vol, only VCR or Vol was added during drug encapsulation. The theoretical DLC of VCR and Vol were 5.0 and 16.7 wt.%, respectively. The particle size and particle size distribution of the two were similar to those of Ps-VCR / Vol. The actual DLC was 4.0 and 13.8 wt.%, respectively, and the encapsulation efficiency was 80.3% and 80.0%, respectively. Ps-VCR / Vol 1 / 24 Has good dilution and serum stability ( Figure 3 B).

[0064] Table 1 Characterization of Ps-VCR / Vol loaded with different VCR and Vol mass ratios

[0065] a Determined by HPLC; b Measured by UV-vis; c Measured by DLS.

[0066] Based on PEG-P(TMC-DTC)-AcKD 10 The particle size of Ps-VCR / Vol prepared by polymer with different drug ratios was between 28.5-29.6 nm, and the particle size distribution was less than 0.1. The DLE of VCR and Vol were 47.1-48.9% and 72.6-73.7%, respectively (Table 2). When the mass feed ratio of VCR to Vol was 1∶8, 1∶16, and 1∶32, respectively, the actual mass ratio of VCR and Vol encapsulated was 1∶12.5, 1∶24.2, and 1∶48.0. The preparation of Ps-VCR and Ps-Vol was similar to that of Ps-VCR / Vol. Only VCR or Vol was added during the drug encapsulation process. The theoretical DLC of VCR and Vol were 5 wt.% and 16.7 wt.%, respectively. The particle size and particle size distribution of the two were similar to those of Ps-VCR / Vol, and the actual DLC was 4.10 wt.% and 13.27 wt.%, respectively.

[0067] Table 2 Based on PEG-P(TMC-DTC)-AcKD 10 Characterization of Ps-VCR / Vol with different VCR and Vol mass ratios

[0068] a Determined by HPLC; bMeasured by UV-vis; c Measured by DLS.

[0069] According to the above method, PEG-P(TMC-DTC)-KD z PEG-P(TMC-DTC)-AcKD z PEG-P(CL-DTC)-KD z PEG-P(CL-DTC)-AcKD z PEG-P(LA-DTC)-KD z 、PEG-P(LA-DTC)-AcKD z Loading VCR and Vol can achieve similar technical effects as those in Table 1, such as PEG 5k -P(TMC 10k -DTC 1.5k )-KD 10 / PEG 5k -P(TMC 10k -DTC 1.5k )-AcKD 10 PEG 5k -P(TMC 15k -DTC 2k )-KD 15 / PEG 5k -P(TMC 15k -DTC 2k )-AcKD 15 PEG 5k -P(TMC 15k -DTC 2k )-KD 5 / PEG 5k -P(TMC 15k -DTC 2k )-AcKD 5 PEG 5k -P(CL 15k -DTC 2k )-KD 10 / PEG 5k -P(CL 15k -DTC 2k )-AcKD 10 PEG 5k -P(LA 15k -DTC 2k )-KD 10 / PEG 5k -P(LA 15k -DTC 2k )-AcKD 10 PEG 7.5k-P(TMC 15k -DTC 2k )-KD 10 / PEG 7.5k -P(TMC 15k -DTC 2k )-AcKD 10 .

[0070] Example 3 In vitro synergistic anti-ALL experiment of Ps-VCR / Vol The synergistic antitumor activity of Ps-VCR / Vol at different drug ratios in CCRF-CEM T-ALL and Nalm-6-Luc B-ALL cells was determined using the CCK-8 kit. All cells were cultured in RPMI-1640 medium containing 10% FBS, 1% penicillin and streptomycin. CCRF-CEM and Nalm-6-Luc cells were plated in 96-well plates (2 × 10 4 Each well was added with 20 μL of different concentrations of Ps-VCR, Ps-Vol, Ps-VCR / Vol 1 / 12 、Ps-VCR / Vol 1 / 24 、Ps-VCR / Vol 1 / 48 (Based on PEG-P(TMC-DTC)-KD 10 Polymer prepared) and free VCR / Vol 1 / 24 , incubated in the incubator for 48 h. The in-well concentration of VCR in the Ps-VCR group was 0.01-100 ng / mL, and the in-well concentration of Vol in the Ps-Vol and dual-drug combination groups was 0.5-50 ng / mL. After incubation for 48 h, 10 µL of CCK-8 solution was added to each well, and the absorbance at 450 nm was tested with a microplate reader after further incubation for 4 h (n = 6). The cell viability was the ratio of the absorbance of the cells in the sample group to the absorbance of the cells in the PBS group. The synergistic effect of VCR and Vol was evaluated by calculating the Combination Index (CI). That is:

[0071] When CI < 1, it is a synergistic effect; when CI < 0.7, it is a strong synergistic effect; when CI = 1, it is an additive effect; when CI > 1, it is an antagonistic effect.

[0072] Figure 4 The results of Ps-VCR / Vol synergistically inhibiting the proliferation of CCRF-CEM and Nalm-6-Luc cells. The study found that both Ps-VCR and Ps-Vol can effectively inhibit the proliferation of CCRF-CEM cells. The IC 501.94 ng / mL and 16.98 ng / mL respectively ( Figure 4 A and Table 3). Compared with Ps-VCR and Ps-Vol single-drug vesicles, Ps-VCR / Vol dual-drug vesicles showed significantly enhanced synergistic anti-ALL activity at mass ratios of VCR to Vol of 1:12, 1:24, and 1:48, with CI values ​​of 0.46, 0.46, and 0.47, respectively. Free VCR / Vol 1 / 24 The anti-ALL activity is weak, and the IC of Vol 50 The value is Ps-VCR / Vol 1 / 24 3.3 times higher.

[0073] Similarly, the Ps-VCR / Vol dual-drug vesicle preparation also had significant synergistic anti-ALL activity in Nalm-6-Luc cells. When the mass ratio of VCR to Vol was 1:12, 1:24, and 1:48, the CI values ​​were 0.48, 0.32, and 0.54, respectively ( Figure 4 B and Table 2). Among them, the synergistic effect was strongest when the ratio of VCR to Vol was 1:24. 50 The values ​​were reduced by 23.4 and 3.6 times compared with the single-drug vesicle preparation. 1 / 24 The anti-ALL activity is weak, and the IC of Vol 50 The value is Ps-VCR / Vol 1 / 24 This indicates that the synergistic effect of the vesicle preparation co-loaded with VCR and Vol is significantly better than that of the free drug combination.

[0074] Table 3 Based on PEG-P(TMC-DTC)-KD 10 Synergistic effect of Ps-VCR / Vol with different VCR and Vol mass ratios in ALL cells

[0075] Based on PEG-P(TMC-DTC)-AcKD 10 The synergistic antitumor activity of Ps-VCR / Vol with different drug ratios in CCRF-CEM cells was also determined using the above method. The in-well concentration of VCR in the Ps-VCR group was 0.01-100 ng / mL, and the in-well concentration of Vol in the Ps-Vol and dual-drug combination groups was 0.1-200 ng / mL. Figure 5 As shown in Table 4, the anti-ALL activity of Ps-VCR / Vol with different drug ratios was significantly improved compared with Ps-VCR and Ps-Vol. The IC 50The values ​​were 0.14-0.42 ng / mL and 4.98-6.69 ng / mL, and the CI values ​​were 0.48-0.51, respectively.

[0076] Table 4 Based on PEG-P(TMC-DTC)-AcKD 10 Synergistic effect of Ps-VCR / Vol prepared with different VCR and Vol mass ratios in CCRF-CEM ALL cells

[0077] The Ps-VCR / Vol used in subsequent experiments was based on PEG-P(TMC-DTC)-KD 10 Polymer preparation.

[0078] Example 4 Ps-VCR / Vol 1 / 24 Induces cell cycle arrest in ALL Ps-VCR / Vol 1 / 24 The induction of ALL cell cycle arrest was investigated by PI / RNase A staining. 1.8 mL of CCRF-CEM or Nalm-6-Luc cells were plated in 6-well plates (5 × 10 5 1 well / well), add 0.2 mL PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, respectively. 1 / 24 and free VCR / Vol 1 / 24 . The in-well concentration of VCR in Ps-VCR was 0.42 ng / mL, and the concentration of Vol in other groups was fixed at 10 ng / mL. After incubation in the incubator for 24 h, the cells were collected by centrifugation and resuspended with 1 mL of ice PBS. The cells were slowly added to 4 mL of 95% ethanol in a vortex state and fixed at 4 ºC for 24 h. Then, the cells were washed with PBS and resuspended in 0.4 mL of staining buffer. 15 µL of PI and 4 µL of RNase A (2.5 mg / mL) were added to each sample group. After staining at 37 ºC for 30 min, the cells were directly tested by flow cytometry. The results showed that in CCRF-CEM cells, Ps-VCR / Vol 1 / 24 When the concentration of Vol was 10 ng / mL, it was able to efficiently induce cell G2 / M phase arrest, and the proportion of cells in the G2 / M phase increased significantly from 8.0% in the PBS group to 46.7%, while the proportions of cells in the G2 / M phase of the vesicle single-drug preparations Ps-VCR and Ps-Vol were 11.2% and 22.1%, respectively ( Figure 6 A, C). In addition, free VCR / Vol 1 / 24 The group also induced only 12.9% G2 / M arrest, which was significantly lower than that of Ps-VCR / Vol 1 / 24In Nalm-6-Luc cells, Ps-VCR / Vol 1 / 24 The proportion of G2 / M phase cells in the PBS group increased significantly from 23.0% to 50.8%, which was significantly higher than that of the vesicle single-drug preparations Ps-VCR (28.4%) and Ps-Vol (22.8%), as well as free VCR / Vol. 1 / 24 (22.6%) ( Figure 6 B, D).

[0079] Example 5 Ps-VCR / Vol 1 / 24 Induces apoptosis of ALL cells Both VCR and Vol can induce cell cycle arrest, thus causing cell apoptosis. To this end, we further used the Annexin V-APC / 7-AAD double staining apoptosis kit to study the Ps-VCR / Vol 1 / 24 Induction of apoptosis in ALL cells. 1.8 mL CCRF-CEM or Nalm-6-Luc cells were plated into 6-well plates (5 × 10 5 1 well / well), add 0.2 mL PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, respectively. 1 / 24 and free VCR / Vol 1 / 24 The concentration of Ps-VCR in the VCR well was 0.21 ng / mL, and the concentration of Vol in other groups was kept constant at 5 ng / mL. After incubation in the incubator for 48 h, the cells were collected by centrifugation and resuspended with 0.5 mL 1×binding buffer. 5 µL Annexin V-APC and 10 µL 7-AAD were added to each well. After staining at room temperature for 5 min, the cells were tested by flow cytometry. At least 10,000 cells were collected for each sample. The results showed that in CCRF-CEM cells, the dual-drug vesicle preparation Ps-VCR / Vol 1 / 24 It can induce significant cell apoptosis, with an apoptosis rate of 48.4%, which is significantly higher than Ps-VCR (12.5%), Ps-Vol (20.2%) and free VCR / Vol 1 / 24 Group (20.8%) ( Figure 7 A). In Nalm-6-Luc cells, the dual-drug vesicle formulation Ps-VCR / Vol 1 / 24 It can also effectively induce cell apoptosis, with an apoptosis rate of up to 80.8%, which is significantly higher than Ps-VCR (44.2%), Ps-Vol (22.7%) and free VCR / Vol 1 / 24 Group (14.0%) ( Figure 7 B). It can be seen that Ps-VCR / Vol 1 / 24It can effectively induce ALL cells to arrest in the G2 / M phase, thereby promoting cell apoptosis, and its effect is significantly better than that of Ps-VCR and Ps-Vol vesicle single-drug preparations and free VCR / Vol 1 / 24 , with obvious synergistic effect.

[0080] Example 6 Ps-VCR / Vol 1 / 24 Cytotoxicity to normal human T cells In order to study Ps-VCR / Vol 1 / 24 With free VCR / Vol 1 / 24 The killing effect on normal human cells was determined by CCK-8 kit to measure Ps-VCR / Vol 1 / 24 With free VCR / Vol 1 / 24 Killing effect on activated human T cells. Activated human T cells were cultured in T cell culture medium containing IL-7, IL-10 and Transact. Activated human T cells were plated in 96-well plates (2 × 10 4 Each well was added with 20 μL of different concentrations of Ps-VCR / Vol 1 / 24 With free VCR / Vol 1 / 24 , incubated in the incubator for 48 h. The concentration of Vol in the wells was 1-100 ng / mL. After incubation for 48 h, 10 µL of CCK-8 solution was added to each well, and the absorbance at 450 nm was tested using a microplate reader after incubation for another 4 h (n = 6). The cell viability was the ratio of the absorbance of the sample group cells to the absorbance of the PBS group cells. The results showed that when the concentration of Vol was as high as 100 ng / mL, Ps-VCR / Vol 1 / 24 The cell survival rate of the group was still 89%, while free VCR / Vol 1 / 24 When the Vol concentration was 50 ng / mL, the cell survival rate was only about 50% ( Figure 8 ), indicating that Ps-VCR / Vol has no obvious toxicity to normal human T cells and has good safety.

[0081] Embodiment 7 Ps-VCR / Vol 1 / 24 Synergistic anti-T-ALL activity in vivo All animal experiments were approved by the Experimental Animal Center of Soochow University and the Suzhou Animal Care and Use Committee, and all animal experimental operations were in compliance with the Animal Care and Use Operation Regulations of Soochow University. 1 / 24 The in vivo synergistic anti-T-ALL activity of ANTI-CCRF was investigated using an orthotopic CCRF-CEM-bearing (T-ALL CDX) mouse model and a patient-derived T-ALL xenograft model (PDX).

[0082] To establish the in situ CCRF-CEM model, 200 μL CCRF-CEM cell suspension (5 × 10 5 ) were injected into 7-8 week old NOD / ShiLtJGpt-Prkdc cells via tail vein em26Cd52 Iq em26Cd22 / Gpt (NCG) female mice, and the day of inoculation was recorded as day 0. On the 5th day after inoculation, the orthotopic CCRF-CEM mouse model was randomly divided into 5 groups and injected with PBS, Ps-VCR (0.25 mg VCR equiv. / kg), Ps-Vol (6 mg Vol equiv. / kg), Ps-VCR / Vol through the tail vein, respectively. 1 / 24 (0.25 mg VCR&6 mg Vol equiv. / kg) and free VCR / Vol 1 / 24 (0.25 mg VCR & 6 mg Vol / kg), once every 4 days, for a total of 5 injections ( Fig. 9 A). There were 10 mice in each group, 6 of which were used for weight and survival monitoring, and 4 for tumor infiltration and micro-CT analysis. During the treatment period, free VCR / Vol 1 / 24 The body weight of mice in the 4 groups decreased by 25.2%, and one mouse died. The body weight of mice in the other groups did not decrease significantly ( Fig. 9 C). It was also observed that the mice in the PBS group developed symptoms rapidly, such as hind limb paralysis and poor mental state, around the 25th day after inoculation, and died quickly, with a median survival of 27 days. Ps-VCR / Vol 1 / 24 The median survival time (MST) of mice was extended to 63.5 days, which was 2.4 times longer than that of the PBS group (***p<0.001), and was significantly better than that of Ps-VCR (MST: 33 days), Ps-Vol (MST: 43 days) and free VCR / Vol 1 / 24 (MST: 48.5 days) group (***p<0.001) ( Fig. 9 B). On the 25th and 39th days, the tumor infiltration in the peripheral blood of mice was detected by flow cytometry. The results showed that on the 25th day, the tumor cells in the peripheral blood of mice in the PBS group accounted for 26.3%, and Ps-VCR inhibited the leukemia infiltration to a certain extent, accounting for 4.0%, while the other treatment groups effectively inhibited the proliferation of leukemia cells in vivo, and no obvious infiltration was observed in the peripheral blood ( Fig.10 A, B). On day 39, Ps-Vol and free VCR / Vol 1 / 24 The tumor infiltration rates in the peripheral blood of mice in the Ps-VCR / Vol 1 / 24No tumor cells were detected in the peripheral blood of mice in the treatment group. These results indicate that Ps-VCR / Vol 1 / 24 It can effectively inhibit the proliferation of leukemia cells and peripheral blood infiltration.

[0083] Subsequently, Ps-Vol, free VCR / Vol were dissected on day 40. 1 / 24 and Ps-VCR / Vol 1 / 24 The tumor infiltration in the peripheral blood, spleen, liver, lung and bone marrow of mice in the PBS group and Ps-VCR group was detected by flow cytometry and compared with that in the PBS group and Ps-VCR group (experimental endpoint). The results showed that leukemia cells proliferated in large numbers in the mice in the PBS and Ps-VCR groups and highly invaded the liver, spleen and bone marrow of mice. The tumor infiltration rate was as high as more than 90%, and the spleen was enlarged, with a weight of up to about 600 mg ( Fig.10 CE). Ps-Vol and free VCR / Vol 1 / 24 There were also a large number of leukemia cells infiltrating in various tissues and organs of mice in the Ps-Vol group. In the spleen and liver, the leukemia cell infiltration was as high as more than 90%, and the infiltration in the bone marrow was more than 80%; free VCR / Vol 1 / 24 The proportion of leukemia cells in the bone marrow, spleen, and liver of the two groups ranged from 74.5% to 86.6%, and the spleen weights of the two groups of mice were as high as 500 and 300 mg, respectively. 1 / 24 The infiltration rates of various organs of mice were all lower than 2%, which was significantly higher than that of PBS, Ps-VCR, Ps-Vol and free VCR / Vol. 1 / 24 The Ps-VCR / Vol 1 / 24 The mice in the control group did not have splenomegaly, and the spleen weight was about 61 mg, which was 1 / 8-1 / 5 of that in other control groups. These results showed that Ps-VCR / Vol had good safety and excellent synergistic anti-tumor activity in the in situ CCRF-CEMT-ALL model.

[0084] At the same time, the heart, liver, spleen, lung, kidney and other major organs and hind leg bones of the mice in each group were collected and fixed with 4% paraformaldehyde and embedded in paraffin, and pathological and histological analysis was performed by H&E. The results showed that the liver, spleen, bone marrow and lungs of the mice in the PBS group were almost completely invaded by T-ALL cells, and Ps-VCR, Ps-Vol and free VCR / Vol were significantly increased. 1 / 24 The T-ALL cells in the liver, spleen, bone marrow and lung of the mice in the PBS group were reduced to a certain extent compared with those in the PBS group, but a large number of hematopoietic tissue cells in the bone marrow disappeared ( Fig.11 A, B). And Ps-VCR / Vol 1 / 24No obvious leukemia cells were found in the organs of the PBS group, which were no different from normal organ tissues, and no toxicity-related damage was observed. The above results are consistent with the infiltration results measured by flow cytometry. The massive proliferation of tumor cells in the bone marrow cavity will cause osteolytic destruction and cause bone pain. We further used micro-CT to observe the bone tissue structure of each group of mice. The results showed that a large number of trabeculae disappeared in the bone marrow cavity of the PBS group mice, and there was osteolysis in the cortical bone ( Fig.12 A). Ps-VCR and Ps-Vol vesicles alone and free VCR / Vol 1 / 24 Although the trabecular bone was improved compared with the PBS group, it was still at a low level. 1 / 24 It can significantly alleviate bone destruction. Quantitative analysis further showed that Ps-VCR / Vol 1 / 24 After treatment, the bone mineral density, bone volume fraction, bone surface area, trabecular thickness, and trabecular number of the mice's leg bones were significantly increased, and the trabecular separation was reduced, which was significantly better than the vesicle single drug group and free VCR / Vol. 1 / 24 Group( Fig.12 B).

[0085] In order to further verify the Ps-VCR / Vol 1 / 24 To demonstrate the synergistic anti-T-ALL effect in vivo, a patient-derived T-ALL orthotopic model (PDX) was established. 200 μL of patient-derived T-ALL cell suspension (1 × 10 6 ) were injected into 7-8 week old NOD.Cg-Prkdc cells via tail vein scid Iq tm1Vst / Vst(NPG) female mice, the day of inoculation was recorded as day 0 ( Fig.13 A). The mice were divided into groups and given PBS, Ps-VCR, Ps-Vol, Ps-VCR / Vol, and Ps-VCR / Vol on the 3rd day after inoculation. 1 / 24 and free VCR / Vol 1 / 24 The dosage and frequency of administration were consistent with those in the in situ CCRF-CEM mouse model. The weight and survival of mice were continuously monitored during and after the administration, and the tumor infiltration in the peripheral blood of each group of mice was detected on days 24, 32, 39, 46, and 52. The results showed that 8.5% of the peripheral blood of mice in the PBS group had tumor infiltration on day 24, and the tumor progressed rapidly. All mice died within 3 days, with a median survival of 25.5 days ( Fig.13 BD). Ps-Vol, freeVCR / Vol 1 / 24The mice in the Ps-VCR and Ps-VCR groups showed obvious peripheral blood tumor infiltration on days 32 and 46, respectively, with leukemia cell percentages of 9.4%, 25.5%, and 8.9%, respectively, and median survival times of 39.5, 47, and 53 days, respectively. 1 / 24 No tumor infiltration was observed in the mice in the group at 52 days. The mice were in good condition with a median survival of 71 days, which was 2.8 times longer than that in the PBS group (MST: 25.5 days) and significantly better than those in the Ps-VCR group (MST: 53 days) (***p<0.001), Ps-Vol group (MST: 39.5 days) (***p<0.001) and free VCR / Vol group (MST: 53 days) (***p<0.001). 1 / 24 (MST: 47 days) (***p<0.001) and other control groups. The body weights of mice in all groups were normal during the treatment period, and no obvious toxic side effects occurred ( Fig.13 E). The above results show that Ps-VCR / Vol 1 / 24 It has potent synergistic anti-T-ALL activity in vivo and demonstrates excellent therapeutic effects in both orthotopic T-ALL CDX and PDX models.

[0086] Embodiment 8 Ps-VCR / Vol 1 / 24 Synergistic anti-B-ALL activity in vivo In order to further verify the Ps-VCR / Vol 1 / 24 To demonstrate the synergistic anti-B-ALL effect in vivo, 200 μL Nalm-6-LucB-ALL cell suspension (5 × 10 5 The orthotopic Nalm-6-Luc B-ALL model was established by injecting 100 mg / kg of dapoxetine into 7- to 8-week-old NCG female mice via the tail vein. The day of inoculation was designated as day 0 ( Fig.14 A). On the 5th day after inoculation, 10 mice were divided into groups and given PBS and Ps-VCR / Vol. 1 / 24 The dosage and frequency of administration were consistent with those in the orthotopic CCRF-CEM mouse model. There were 10 mice in each group, 6 for weight and survival monitoring, and 4 for detecting tumor infiltration and observing tumor distribution and growth through mouse live imaging. The results of mouse bioluminescence imaging showed that Ps-VCR / Vol 1 / 24 No tumor signal was observed in the mice of group A during the period of 14-23 days, and the bioluminescence signal was maintained at 5.2 × 10 5 p / s, which is comparable to the background signal of healthy mice ( Fig.14 B, C). The tumor signal in the PBS group mice increased rapidly, and the bioluminescence signal reached 1.1 × 10 10 p / s, is Ps-VCR / Vol 1 / 24The Ps-VCR / Vol 1 / 24 The survival of mice was significantly prolonged, with a median survival time of 63.5 days, which was 2.6 times longer than that of the PBS group (24 days). Fig.14 D). During the treatment period, there was no significant decrease in the body weight of mice ( Fig.14 E).

[0087] On the 23rd day, the mice in each group were dissected and the tumor infiltration in the peripheral blood, spleen, liver, lung and bone marrow of the mice was detected by flow cytometry. The results showed that the tumor cells in the PBS group were highly infiltrated in various tissues and organs, with the infiltration rates in the liver, spleen, bone marrow, lung and peripheral blood being 80.9%, 72.8%, 58.9%, 36.6% and 28.0%, respectively. In contrast, Ps-VCR / Vol 1 / 24 The infiltration of each organ in the mice in the PBS group was less than 0.6%, which was 135-5890 times lower than that in the PBS group ( Fig.15 A, B). In addition, Ps-VCR / Vol 1 / 24 The mice in the PBS group had no splenomegaly and their spleen weight was 46.5 mg, which was comparable to that of healthy mice. However, the spleen weight of the mice in the PBS group was as high as 175 mg, which was higher than that of the Ps-VCR / Vol 1 / 24 The level of β-catenin in the control group was 3.8 times higher than that in the control group ( Fig.15 C). The above results show that Ps-VCR / Vol 1 / 24 It has strong synergistic anti-B-ALL activity in vivo, greatly reduces tumor infiltration in mice, reduces the tumor burden of mice, and significantly prolongs the survival of mice.

[0088] At the 23rd day of autopsy, the spleen, liver, lung, heart, kidney and leg bones of mice in each group were collected for H&E staining analysis. The study showed that there were a large number of tumor cells in the spleen, liver and lung of mice in the PBS group, while in the Ps-VCR / Vol 1 / 24 No tumor cells were observed in these organs of mice in the Fig.16 ). In addition, the hearts and kidneys of the two groups of mice maintained good morphology and showed no damage to these two organs. In addition, the pictures of the leg bones showed that there was severe tumor cell invasion in the femur and tibia of the PBS group mice, and the hematopoietic tissue was severely damaged, resulting in a large number of hematopoietic cells disappearing. 1 / 24 The mice in the control group had complete hematopoietic function and hematopoietic tissue structure.

[0089] For those skilled in the art, various other corresponding changes and deformations can be made according to the technical solutions and concepts described above, and all of these changes and deformations should fall within the protection scope of the claims of the present invention.

Claims

1. Application of a drug-co-loaded polymer vesicle in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The drug-co-loaded polymer vesicles are mainly prepared from amphiphilic block polymers and two or more anti-tumor drugs, wherein the amphiphilic block polymers are hydrophilic segment-hydrophobic segment-polypeptide segment.

2. Use of the drug-co-loaded polymer vesicles according to claim 1 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The amphiphilic block polymer is a hydrophilic segment-hydrophobic segment-KD z , wherein K is lysine, D is aspartic acid, the hydrophilic segment is a polyethylene glycol segment, the hydrophobic segment is a random copolymer P(A-DTC), A is an ester monomer or a carbonate monomer unit, and DTC is a disulfide five-membered ring carbonate unit; z is 1 to 25; the ester monomer is one or two of caprolactone and lactide; and the carbonate monomer is trimethylene carbonate.

3. Use of the drug-co-loaded polymer vesicles according to claim 1 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The structure of the amphiphilic block polymer is hydrophilic segment-hydrophobic segment-AcKD z , wherein K is lysine, D is aspartic acid, Ac is acetyl, the hydrophilic segment is a polyethylene glycol segment, the hydrophobic segment is a random copolymer P (A-DTC), A is an ester monomer or a carbonate monomer unit, DTC is a disulfide five-membered ring carbonate unit; z is 1 to 25; the ester monomer is one or two of caprolactone and lactide; the carbonate monomer is trimethylene carbonate.

4. Use of the drug-co-loaded polymer vesicles according to claim 1, 2 or 3 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The anti-tumor drug is a combination of a microtubule inhibitor and a Polo-like kinase 1 inhibitor targeting oncogenes.

5. Use of the drug-co-loaded polymer vesicles according to claim 4 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The microtubule protein inhibitor is any one or more of vincristine sulfate, paclitaxel, docetaxel, cabazitaxel, auristatin, maytansine, and eribulin.

6. Use of the drug-co-loaded polymer vesicles according to claim 4 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The inhibitor targeting oncogene Polo-like kinase 1 is any one or more of volacetidine, reglucicetidine, ON01910, BI2536, HMN-214, and GSK461364.

7. Use of the drug-co-loaded polymer vesicles according to claim 4 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The feeding mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1: (1-48).

8. Use of the drug-co-loaded polymer vesicles according to claim 4 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that In the drug-co-loaded polymer vesicles, the actual encapsulation mass ratio of the microtubule protein inhibitor to the inhibitor targeting the oncogene Polo-like kinase 1 is 1: (1-48).

9. Use of the drug-co-loaded polymer vesicles according to claim 2 or 3 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that In the amphiphilic block polymer, the molecular weight of the hydrophilic segment is 2000-10000Da; the molecular weight of the hydrophobic segment is 2-10 times that of the hydrophilic segment; the molecular weight of PDTC is 10%-40% of the total molecular weight of the hydrophobic segment; and z is 5-15.

10. Use of the drug-co-loaded polymer vesicles according to any one of claims 1 to 9 in the preparation of a drug for treating acute lymphoblastic leukemia, It is characterized in that The structure of the amphiphilic block polymer is any one of the following structures: 。 11. Use of a drug-co-loaded polymer vesicle in the preparation of a drug for treating acute lymphoblastic leukemia. It is characterized in that The drug-co-loaded polymer vesicles are mainly prepared from amphiphilic block polymers, tubulin inhibitors, and inhibitors targeting oncogene Polo-like kinase 1, wherein the structure of the amphiphilic block polymer is any one of the following structures: ; The microtubule protein inhibitor is vincristine sulfate, and the inhibitor targeting oncogene Polo-like kinase 1 is volacetide; the feeding mass ratio of the microtubule protein inhibitor to the inhibitor targeting oncogene Polo-like kinase 1 is 1: (1-48).